ClinicalTrials.gg
CompletedNCT03775434Updated Aug 5, 2024Results posted

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

A Phase 1 interventional study of Experimental: B244 in Eczema and Atopic Dermatitis, sponsored by AOBiome LLC. Completed at 6 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-05.

Sponsored by AOBiome LLC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Eczema with a site in United States — 33 open to participants now, 47 under way, 9 of them phase 3. Eczema · United States.

Enrollment
173rd of 216
28 · median 102
Started
2018
with 25 others
Phase 1
18 of 251
3 open now
Registered
117th of 251
by date

Among the 251 studies in Eczema with a site in United States, this one is the 173rd largest by enrollment of the 216 interventional ones that give a count, is one of 26 that started in 2018, is one of 18 in phase 1, and was the 117th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

33 of the 251 studies in Eczema with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Eczema with a site in United States, or all of them as a file.
02

Study summary

An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis

Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b

Read the detailed description

This is a Phase 1b, open-label, single arm, multiple site study assessing twice daily B244 application for 28 days in pediatric subjects with mild to moderate atopic dermatitis.

Number of Subjects:

The study will enroll 36 subjects in 3 cohorts of 12 subjects:

  • Cohort 1: subjects aged 2 to 5 years.
  • Cohort 2: subjects aged 6 to 11 years.
  • Cohort 3, subjects aged 12 to 17 years.

At Screening and Baseline, all subjects must have confirmed diagnosis of atopic dermatitis, as defined by the Hanifin and Rajka criteria, which involves a minimum of 10% but no more than 60% body surface area and a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) scale of 2 or 3.

The duration of the study will be approximately 7 weeks. Subjects will attend for a Screening visit between Days -21 and -14. If all eligibility criteria and none of the exclusion criteria are met, subjects will be enrolled into the study and will be required to undergo a 14 day washout period (Days-14 to -1). Subjects will attend the study center on Day 1 and the Baseline assessments will be performed before application of the first dose.

On confirmation of continued eligibility the subject and parent or guardian of the subject will be coached on how to apply medication, depending on the affected areas. They will be instructed to apply B244 twice daily (approximately 12 hours apart) for 28 days.

The first dose will be applied in the clinic under the supervision of clinical staff. Details of dose administration will be recorded in the study diary provided. The subjects with their parent or guardian will return to the study center on Days 7, 14, and 21 for completion of study assessments.

There will be a final study visit on Day 28, this will be defined as the end of the study for the subjects. A time window of ±2 day will be permitted for these 4 visits. There will not be a period of confinement in the study center all visits will be outpatient visits. Safety monitoring will include review of TEAEs, vital signs and physical examination. Efficacy will be assessed using EASI, vIGA-AD scale, POEM and ItchMan scores.

03

Conditions studied

  • Eczema
  • Atopic Dermatitis
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are eligible to be included in the study only if all of the following criteria apply:

    1. Male and female subjects 2 to 17 years of age, inclusive.
    2. Confirmed diagnosis of atopic dermatitis according to the Hanifin and Rajka criteria.
    3. A minimum of 10% but no more than 60% of the subjects' body surface area (see Appendix 6 for guidance) is affected by atopic dermatitis (affected is defined by physical examination findings: erythema, edema, scaling, lichenification, and excoriation; with the excoriation serving as the physical examination correlate of pruritus).
    4. A vIGA-AD scale of 2 or 3 at Screening and Baseline.
    5. Subject, or the parent or guardian, to provide written and authorization for protected health information disclosure.
    6. Subjects must be generally in good health based on Investigator's assessment (other than atopic dermatitis).
    7. Normal vital signs, or with no vital signs that in the opinion of the Investigator, would place the subject at increased risk or would confound the objectives of the study.
    8. Females must not be pregnant, as confirmed by negative urine pregnancy testing. Female subjects aged ≥11 years old, or female patients \<11 years old who have started menstruating, will have urinary pregnancy test performed at Screening and prior to the first dose with negative results in order to participate in the study. Females must either practice abstinence from heterosexual contact or use one of the highly effective options described in the Appendix 5.
    9. Male subjects of , must be willing to practice effective contraception during the study while receiving study treatment from Day 1 and for 7 days after the last study visit (Day 28).
    10. Ability to comprehend and comply with study procedures.
    11. Agree to commit to participate in the current protocol.
    12. Provide written informed consent prior to any study procedure being performed.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria apply:

<!-- -->

  1. physical or mental disorder which, in the opinion of the Investigator, would place the subject at increased risk or would confound the objectives of the study.
  2. Subjects with atopic dermatitis on the face only.
  3. Active cutaneous bacterial, viral or fungal infection in any treatment area at Baseline (eg, clinically infected atopic dermatitis).
  4. History or presence of immunological deficiencies or diseases, organ transplant, (HIV), diabetes, , malignant or pre-malignant skin conditions, serious active or recurrent infection, systemic regimens, clinically significant renal disease severe hepatic disorders, or other severe uncontrolled conditions (eg, drug or alcohol abuse), that are significant and/or that may pose a health risk to the subject in the study or may have an impact on the study assessments.
  5. Unstable atopic dermatitis or a consistent requirement for high-potency (class I-III steroids).
  6. Active systemic or localized infection (including infected AD).
  7. Subjects unable to comply with the excluded medication/therapy restriction
  8. Known to the study treatment.
  9. Known to have , or HIV I or II tests. Details will be recorded in medical history, a blood sample will not be collected for confirmation.
  10. Female subject who is pregnant, breastfeeding, or considering pregnancy during the study.
  11. Any skin condition which in the Investigator's opinion may interfere with the evaluation of atopic dermatitis.
  12. Use of any drugs within the previous 30 days prior to dosing or within a period of less than 5 times the drug's half-life, whichever is longer.
  13. Use of any biologic within a period of 5 times its half-life.
  14. Children or relatives of the Sponsor, clinical research organization, or the Study Site personnel are excluded from participating in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    B244

    B244 suspension in 30ml/bottle

    Drug: Experimental: B244

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0

    Safety and tolerability endpoints will consist of all adverse events reporting from Baseline to Day 28.

    Time frame: Baseline to Day 28

  2. Number of Participants With Clinically Significant Changes From Baseline in Physical Exam.

    A physical exam will be conducted by a physician assessing systems (General appearance, Dermatological, Musculoskeletal, Thyroid, HEENT \[Head, eyes, ears, nose, throat\], Lymphatic, Respiratory, Gastrointestinal, Cardiovascular, Neurological, Extremities, and other). Clinical significance of the physical exam will be determined at investigator's discretion. Results for each system were assessed as Normal, Abnormal CS (clinically significant), or Abnormal NCS (not clinically significant) and shift was analyzed from Baseline to Day 28.

    Time frame: Baseline to Day 28

  3. Mean Change in Blood Pressure From Baseline at Day 28

    Blood pressure will be obtained (mmHg). Clinical significance of blood pressure will be determined at the investigator's discretion. Change from Day 28 to Baseline.

    Time frame: Baseline to Day 28

  4. Mean Change in Pulse Rate From Baseline at Day 28

    Pulse rate (beats per minute \[bpm\]) will be obtained. Clinical significance of pulse rate will be determined at the investigator's discretion. Change from Day 28 to Baseline.

    Time frame: Baseline to Day 28

  5. Mean Change in Body Temperature From Baseline at Day 28

    Body temperature (°C) will be obtained. Clinical significance of body temperature will be determined at the investigator's discretion. Change from Day 28 to Baseline.

    Time frame: Baseline to Day 28

Other outcomes

  1. Changes in the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).

    The vIGA-AD is a physician assessment ranking of Atopic Dermatitis symptoms from 0-clear, to 4- severe.

    Time frame: Baseline, Days 7, 14, 21, and 28

  2. Changes in Area Severity Index (EASI) Score.

    EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0 to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.

    Time frame: Baseline, Days 7, 14, 21, and 28

  3. Changes in Patient Oriented Eczema Measure (POEM Total Score).

    POEM is a survey that consists of 7 questions that assesses the quality of life of patient's with eczema to determine their disease severity. The 7 questions are scored out of 4 points based on frequency of occurrence during the prior week (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days). A higher total score indicates a higher severity of disease (0 \[clear\] to 28 \[very severe\]).

    Time frame: Baseline, Days 7, 14, 21, and 28

  4. Changes in Patient Reported Outcome (Self-reported ItchMan Scale).

    The Burn Man Itch Scale is used as a self report tool for subjects to indicate how itchy the area of atopic dermatitis feels at the timepoints during the study. It's reported on a scale between 0-comfortable, no itch and 4-Itches most terribly; impossible to sit still; concentrate.

    Time frame: Baseline, Days 7, 14, 21, and 28

07

Results

Posted Aug 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneB244
Started28
Completed25
Not completed3
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0

Safety and tolerability endpoints will consist of all adverse events reporting from Baseline to Day 28.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0
ParticipantsB244
Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.011
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Physical Exam.

A physical exam will be conducted by a physician assessing systems (General appearance, Dermatological, Musculoskeletal, Thyroid, HEENT \[Head, eyes, ears, nose, throat\], Lymphatic, Respiratory, Gastrointestinal, Cardiovascular, Neurological, Extremities, and other). Clinical significance of the physical exam will be determined at investigator's discretion. Results for each system were assessed as Normal, Abnormal CS (clinically significant), or Abnormal NCS (not clinically significant) and shift was analyzed from Baseline to Day 28.

Time frame:
Baseline to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Physical Exam.
ParticipantsB244
Cardiovascular: Normal -> Normal25
Dermatological: Normal -> Abnormal CS1
Dermatological: Normal -> Normal24
Extremities: Normal -> Normal25
Gastrointestinal: Normal -> Normal25
General Appearance: Abnormal NCS -> Abnormal NCS1
General Appearance: Normal -> Normal24
HEENT: Abnormal CS-> Normal1
HEENT: Normal -> Normal24
Lymphatic: Normal -> Normal25
Musculoskeletal: Normal -> Normal25
Neurological: Normal -> Normal25
Respiratory: Normal -> Abnormal NCS1
Respiratory: Normal -> Normal24
Thyroid: Missing -> Normal1
Thyroid: Normal -> Normal24
PrimaryMean Change in Blood Pressure From Baseline at Day 28

Blood pressure will be obtained (mmHg). Clinical significance of blood pressure will be determined at the investigator's discretion. Change from Day 28 to Baseline.

Time frame:
Baseline to Day 28
Reported as:
Mean · mmHg
Mean Change in Blood Pressure From Baseline at Day 28
mmHgB244
Diastolic Blood Pressure1.6 ± 9.3
Systolic Blood Pressure1.8 ± 10.8
Other pre-specifiedChanges in the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).

The vIGA-AD is a physician assessment ranking of Atopic Dermatitis symptoms from 0-clear, to 4- severe.

Time frame:
Baseline, Days 7, 14, 21, and 28
Reported as:
Count of participants · Participants
Changes in the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).
ParticipantsB244
Change from Baseline on Day 7 — 4 - Worsen by 4 grades0
Change from Baseline on Day 7 — 3 - Worsen by 3 grades0
Change from Baseline on Day 7 — 2 - Worsen by 2 grades0
Change from Baseline on Day 7 — 1 - Worsen by 1 grade2
Change from Baseline on Day 7 — No change23
Change from Baseline on Day 7 — -1 - Improved by 1 grade1
Change from Baseline on Day 7 — -2 - Improved by 2 grades0
Change from Baseline on Day 7 — -3 - Improved by 3 grades0
Change from Baseline on Day 7 — -4 - Improved by 4 grades0
Change from Baseline on Day 14 — 4 - Worsen by 4 grades0
Change from Baseline on Day 14 — 3 - Worsen by 3 grades0
Change from Baseline on Day 14 — 2 - Worsen by 2 grades0
Change from Baseline on Day 14 — 1 - Worsen by 1 grade2
Change from Baseline on Day 14 — No change20
Change from Baseline on Day 14 — -1 - Improved by 1 grade3
Change from Baseline on Day 14 — -2 - Improved by 2 grades0
Change from Baseline on Day 14 — -3 - Improved by 3 grades0
Change from Baseline on Day 14 — -4 - Improved by 4 grades0
Change from Baseline on Day 21 — 4 - Worsen by 4 grades0
Change from Baseline on Day 21 — 3 - Worsen by 3 grades0
Change from Baseline on Day 21 — 2 - Worsen by 2 grades0
Change from Baseline on Day 21 — 1 - Worsen by 1 grade2
Change from Baseline on Day 21 — No change17
Change from Baseline on Day 21 — -1 - Improved by 1 grade6
Change from Baseline on Day 21 — -2 - Improved by 2 grades0
Change from Baseline on Day 21 — -3 - Improved by 3 grades0
Change from Baseline on Day 21 — -4 - Improved by 4 grades0
Change from Baseline on Day 28 — 4 - Worsen by 4 grades0
Change from Baseline on Day 28 — 3 - Worsen by 3 grades0
Change from Baseline on Day 28 — 2 - Worsen by 2 grades0
Change from Baseline on Day 28 — 1 - Worsen by 1 grade2
Change from Baseline on Day 28 — No change17
Change from Baseline on Day 28 — -1 - Improved by 1 grade5
Change from Baseline on Day 28 — -2 - Improved by 2 grades1
Change from Baseline on Day 28 — -3 - Improved by 3 grades0
Change from Baseline on Day 28 — -4 - Improved by 4 grades0
Other pre-specifiedChanges in Area Severity Index (EASI) Score.

EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0 to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.

Time frame:
Baseline, Days 7, 14, 21, and 28
Reported as:
Mean · score on a scale
Changes in Area Severity Index (EASI) Score.
score on a scaleB244
Change from Baseline to Day 7-0.31 ± 2.920
Change from Baseline to Day 14-1.30 ± 4.088
Change from Baseline to Day 21-1.98 ± 4.693
Change from Baseline to Day 28-2.31 ± 4.109
Other pre-specifiedChanges in Patient Oriented Eczema Measure (POEM Total Score).

POEM is a survey that consists of 7 questions that assesses the quality of life of patient's with eczema to determine their disease severity. The 7 questions are scored out of 4 points based on frequency of occurrence during the prior week (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days). A higher total score indicates a higher severity of disease (0 \[clear\] to 28 \[very severe\]).

Time frame:
Baseline, Days 7, 14, 21, and 28
Reported as:
Mean · score on a scale
Changes in Patient Oriented Eczema Measure (POEM Total Score).
score on a scaleB244
Change from Baseline to Day 7-1.2 ± 4.68
Change from Baseline to Day 14-4.2 ± 5.21
Change from Baseline to Day 21-4.4 ± 6.10
Change from Baseline to Day 28-4.2 ± 7.03
Other pre-specifiedChanges in Patient Reported Outcome (Self-reported ItchMan Scale).

The Burn Man Itch Scale is used as a self report tool for subjects to indicate how itchy the area of atopic dermatitis feels at the timepoints during the study. It's reported on a scale between 0-comfortable, no itch and 4-Itches most terribly; impossible to sit still; concentrate.

Time frame:
Baseline, Days 7, 14, 21, and 28
Reported as:
Mean · score on a scale
Changes in Patient Reported Outcome (Self-reported ItchMan Scale).
score on a scaleB244
Change from Baseline to Day 7-0.2 ± 0.92
Change from Baseline to Day 14-0.8 ± 1.20
Change from Baseline to Day 21-0.6 ± 1.26
Change from Baseline to Day 28-0.8 ± 1.40
PrimaryMean Change in Pulse Rate From Baseline at Day 28

Pulse rate (beats per minute \[bpm\]) will be obtained. Clinical significance of pulse rate will be determined at the investigator's discretion. Change from Day 28 to Baseline.

Time frame:
Baseline to Day 28
Reported as:
Mean · bpm
Mean Change in Pulse Rate From Baseline at Day 28
bpmB244
Mean Change in Pulse Rate From Baseline at Day 283.9 ± 15.3
PrimaryMean Change in Body Temperature From Baseline at Day 28

Body temperature (°C) will be obtained. Clinical significance of body temperature will be determined at the investigator's discretion. Change from Day 28 to Baseline.

Time frame:
Baseline to Day 28
Reported as:
Mean · °C
Mean Change in Body Temperature From Baseline at Day 28
°CB244
Mean Change in Body Temperature From Baseline at Day 28-0.2 ± 0.6

Adverse events

Collected over Baseline to Day 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B2440/28 (0%)0/28 (0%)11/28 (39.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventB244
NasopharyngitisInfections and infestations2/28
PruritusSkin and subcutaneous tissue disorders2/28
LymphadenopathyBlood and lymphatic system disorders1/28
VomitingGastrointestinal disorders1/28
MalaiseGeneral disorders1/28
PyrexiaGeneral disorders1/28
Localized infectionInfections and infestations1/28
SinusitisInfections and infestations1/28
Tibia fractureInjury, poisoning and procedural complications1/28
Pain in extremityMusculoskeletal and connective tissue disorders1/28

Baseline characteristics

ITT population: All subjects who were enrolled and took at least 1 dose of study treatment.

Age, Customized
Age, Customized(years)B244
Mean7.4 ± 4.80
Sex: Female, Male
Sex: Female, Male(Participants)B244
Female15
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B244
Hispanic or Latino6
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B244
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White23
More than one race0
Unknown or Not Reported0
Percentage of Total Body Surface Area Affected by Atopic Dermatitis
Percentage of Total Body Surface Area Affected by Atopic Dermatitis(% of total body surface area)B244
Mean17.98 ± 7.581
Baseline vIGA-AD Score
Baseline vIGA-AD Score(Participants)B244
2=Mild11
3=Moderate17
Weight
Weight(kg)B244
Mean36.22 ± 30.599
Height
Height(cm)B244
Mean124.0 ± 29.95

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Dermatology Trial Associates
    Bryant, Arkansas 72022, United States
  • L.A. Universal Research Center, Inc.
    Los Angeles, California 90057, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Virginia Clinical Research, INC
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2019, 5 months.

Results were first posted in Aug 2024, 5 years 2 months after primary completion.

Of 16 phase 1 interventional studies under Eczema, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Dec 14, 2018
StartActual
Dec 7, 2018
Primary completionActual
May 18, 2019
CompletionActual
Jun 10, 2019
Results first posted
Aug 5, 2024
Last update
Aug 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03775434
Lead sponsor
AOBiome LLC
Collaborators
Novella Clinical
Responsible party
Sponsor
First posted
Dec 14, 2018
Start date
Dec 7, 2018
Primary completion
May 18, 2019
Completion
Jun 10, 2019
Results posted
Aug 5, 2024
Last update
Aug 5, 2024

Study contacts

Judith Ng-Cashin, MD
study director · Chief Medical Officer
Spiros Jamas, ScD
study director · AOBiome Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion